WO2003004503A1 - Morpholin-überbrückte pyrazolopyridinderivate - Google Patents
Morpholin-überbrückte pyrazolopyridinderivate Download PDFInfo
- Publication number
- WO2003004503A1 WO2003004503A1 PCT/EP2002/006991 EP0206991W WO03004503A1 WO 2003004503 A1 WO2003004503 A1 WO 2003004503A1 EP 0206991 W EP0206991 W EP 0206991W WO 03004503 A1 WO03004503 A1 WO 03004503A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compound
- compounds
- treatment
- manufacture
- Prior art date
Links
- 0 *c1nc(-c2n[n](Cc(cccc3)c3F)c3c2C=CCN3)nc(*)c1I Chemical compound *c1nc(-c2n[n](Cc(cccc3)c3F)c3c2C=CCN3)nc(*)c1I 0.000 description 3
- FWPBWDMKQQRHHZ-UHFFFAOYSA-N C(c1ccccc1)N1CC(CC2)OC2C1 Chemical compound C(c1ccccc1)N1CC(CC2)OC2C1 FWPBWDMKQQRHHZ-UHFFFAOYSA-N 0.000 description 1
- KZVKXYSMYGMEPB-UHFFFAOYSA-N CCOC(c1n[n](Cc2ccccc2F)c2ncccc12)=O Chemical compound CCOC(c1n[n](Cc2ccccc2F)c2ncccc12)=O KZVKXYSMYGMEPB-UHFFFAOYSA-N 0.000 description 1
- GWDSAMDSGSEPRH-UHFFFAOYSA-N NC(c1n[n](Cc2ccccc2F)c2c1cccn2)=O Chemical compound NC(c1n[n](Cc2ccccc2F)c2c1cccn2)=O GWDSAMDSGSEPRH-UHFFFAOYSA-N 0.000 description 1
- CPNODSARXKSODJ-UHFFFAOYSA-N NC(c1n[n](Cc2ccccc2F)c2ncccc12)N Chemical compound NC(c1n[n](Cc2ccccc2F)c2ncccc12)N CPNODSARXKSODJ-UHFFFAOYSA-N 0.000 description 1
- ZYCSKJLOQJGMCL-UHFFFAOYSA-N OCC1N(Cc2ccccc2)C(CO)CCC1 Chemical compound OCC1N(Cc2ccccc2)C(CO)CCC1 ZYCSKJLOQJGMCL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- the soluble guanylate cyclases consist of two subunits and most likely contain one heme per heterodimer, which is part of the regulatory center. This is of central importance for the activation mechanism. NO can bind to the iron atom of the heme and so the
- guanylate cyclase plays a decisive role in different physiological processes, in particular in the relaxation and proliferation of smooth muscle cells, platelet aggregation and adhesion and neuronal signal transmission as well as in diseases which are based on a disturbance of the above-mentioned processes.
- patho- The NO / cGMP system can be suppressed under physiological conditions, which can lead, for example, to high blood pressure, platelet activation, increased cell proliferation, endothelial dysfunction, atherosclerosis, angina pectoris, heart failure, thromboses, stroke and myocardial infarction.
- a NO-independent treatment option for such diseases aimed at influencing the cGMP signal path in organisms is a promising approach due to the expected high efficiency and few side effects.
- WO 98/16507, WO 98/23619, WO 00/06567, WO 00/06568, WO 00/06569 and WO 00/21954 pyrazolopyridine derivatives are described as stimulators of soluble guanylate cyclase.
- These patent applications also describe pyrazolo-pyridines which have a pyrimidine residue in the 3-position.
- These new pyrazolopyridine derivatives are distinguished by a pyrimidine residue in the 3-position which has a certain substitution pattern, namely a bridged morpholine residue in the 5-position of the pyrimidine ring and one or two amino groups in the 4-position or 4,6-position of the pyrimidine ring.
- the present invention relates to the compounds of the formula (I)
- n 1 or 2;
- R 2 represents H or NH 2 ;
- the present invention relates to compounds of the formula (I) in which
- Physiologically acceptable salts are preferred in the context of the present invention.
- Physiologically acceptable salts of the compound according to the invention can be salts of the substances according to the invention with mineral acids, carboxylic acids or sulfonic acids.
- Physiologically acceptable salts can also be metal or ammonium salts of the compound according to the invention which have a free carboxyl group.
- metal or ammonium salts of the compound according to the invention which have a free carboxyl group.
- sodium, potassium, magnesium or calcium salts and ammonium salts derived from ammonia or organic amines such as ethylamine, di- or triethylamine, di- or triethanolamine, dicyclohexylamine, dimethylaminoethanol, arginine, lysine are particularly preferred or ethylenediamine.
- the compounds of the invention can exist in tautomeric forms. This is known to those skilled in the art, and such forms are also within the scope of the invention.
- the compounds according to the invention can exist in the form of their possible hydrates.
- the compounds of the formula (I) according to the invention can be prepared by reacting the compound of the formula (H)
- R 1 is as defined above;
- Alk stands for linear or branched C M alkyl
- R 1 is as defined above;
- R 1 is as defined above;
- R represents halogen
- the compound of formula (II) can be prepared according to the following reaction scheme:
- the compound of the formula (ET) is obtainable in a multistage synthesis from the literature-known sodium salt of the ethyl cyanobrenzenate (Borsche and Manteuffel, Liebigs. Ann. Chem. 1934, 512, 97).
- 2-fluorobenzylhydrazine By reacting it with 2-fluorobenzylhydrazine while heating and in a protective gas atmosphere in an inert solvent such as dioxane, the 5-amino-l- (2-fluorobenzyl) -pyrazole-3-carboxylic acid ethyl ester is obtained, which is obtained by reaction with dimethylaminoacrolein in acid
- This pyridine derivative l- (2-fluorobenzyl) -IH-pyrazolo [3,4-b] pyridine-3-carboxylic acid ethyl ester is dehydrated by a multistage sequence consisting of converting the ester with ammonia into the corresponding amide converted with a dehydrating agent such as trifluoroacetic anhydride to the corresponding nitrile derivative, reaction of the nitrile derivative with sodium ethylate and final reaction with ammonium chloride in the compound of formula (II).
- the bicyclic system is built up, for example, by reacting the bishydroxymethyltetrahydrofuran derivative (activated as bistosylate) with benzlyamine via a nucleophilic substitution reaction under conditions conventionally used for such reactions.
- the reaction is preferably carried out in an organic solvent, for example a hydrocarbon, preferably an aromatic hydrocarbon and in particular toluene Use of a 2-5-fold excess of the amine preferably at normal pressure and stirring the reaction solution for several hours, for example 2 hours, at elevated temperature, for example 60-130 ° C., preferably 80-120 ° C., in particular 100 ° C.
- the bicyclic system is built up, for example, by an intramolecular nucleophilic substitution reaction of the two hydroxyl groups of the piperidine-2,6-dihydroxymethyl derivative under conditions conventionally used for such reactions.
- it is preferred to carry out the reaction under acidic conditions for example in the presence of concentrated sulfuric acid, preferably under normal pressure and stirring the reaction solution for several hours, for example 24 hours, at elevated temperature, for example 60-200 ° C., preferably 80-190 ° C. especially 175 ° C.
- Protecting group under conditions conventionally used for such reactions gene for example with hydrogen on a palladium / activated carbon catalyst in an organic solvent, for example an alcohol, preferably ethanol, preferably under elevated pressure of 50-200 bar, preferably 100 bar, and stirring the reaction solution for several hours, for example 5 hours, at elevated temperature, for example 60-130 ° C, preferably 80-120 ° C, in particular 100 ° C, are converted into the corresponding bicyclic amines.
- an organic solvent for example an alcohol, preferably ethanol, preferably under elevated pressure of 50-200 bar, preferably 100 bar
- acetonitrile derivatives for example with haloacetonitriles and preferably with bromoacetonitrile, under conditions conventionally used for such reactions, for example in an organic solvent such as N, N-dimethylformamide (DMF), using a slight excess of the acetonitrile derivative in the presence of a base , for example an amine such as N, N-diisopropylethylamine, and a halide such as sodium iodide preferably at normal pressure and stirring the reaction solution for several hours, for example 24 hours, at elevated temperature, for example 40-130 ° C, preferably 40-100 ° C, in particular 60 ° C, to be converted to the corresponding N-methyl nitrile derivatives.
- a base for example an amine such as N, N-diisopropylethylamine
- a halide such as sodium iodide preferably at normal pressure and stirring the reaction solution for several hours, for example 24 hours, at elevated temperature, for
- the compounds of the formula (III) can finally be reacted with a formic acid ester, for example ethyl formate, under conditions conventionally used for such reactions, for example in an organic solvent, for example an ether, preferably a cyclic ether such as
- Tetrahydrofuran using a 2-5-fold excess of formic acid ester, preferably at normal pressure and stirring the reaction solution for several minutes, for example 20-60 minutes, at room temperature, and then acetylating with acetic anhydride in the presence of acetic acid under conventional for such reactions conditions used, for example under
- the reaction of the compounds of the formulas (H) and (HI) to the compounds of the formula (I) can be carried out in equimolar amounts by using the reactants. or using the compound of the formula (III) in a slight excess in an organic solvent, for example a hydrocarbon, preferably an aromatic hydrocarbon and in particular toluene, preferably at normal pressure and stirring the reaction solution for several hours, for example 12 hours, at elevated temperature , for example 80-160 ° C, preferably 100-150 ° C, in particular 120 ° C, are carried out.
- an organic solvent for example a hydrocarbon, preferably an aromatic hydrocarbon and in particular toluene
- the compounds of formula (IV) are commercially available (e.g. from Mercachem) or can be prepared in a manner known to those skilled in the art.
- reaction of the compounds of the formulas (11) and (IV) to the compounds of the formula (V) can be carried out in an organic solvent, for example by using the reactants in equimolar amounts or using the compound of the formula (IV) in a slight excess a hydrocarbon, preferably an aromatic hydrocarbon and in particular
- Toluene preferably at normal pressure and stirring the reaction solution for several hours, for example 12 hours, at elevated temperature, for example 80-160 ° C., preferably 100-150 ° C., in particular 140 ° C.
- reaction of the compounds of the formula (V) to compounds of the formula (VI) can be carried out by reacting the compounds of the formula (V) with a halogenating agent, if appropriate in an organic solvent such as dimethylformamide (DMF) conventionally used for such reactions, preferably at normal pressure and stirring the reaction solution for several hours, for example 3 hours, at elevated temperature, for example 80-
- a halogenating agent if appropriate in an organic solvent such as dimethylformamide (DMF) conventionally used for such reactions
- POCl 3 can preferably be used as the halogenating agent.
- reaction of the compounds of the formula (VI) to the compounds of the formula (I) according to the invention can be carried out by reaction of the compounds of the formula (VI) with aqueous ammonia solution, preferably at elevated pressure, for example by running the reaction in an autoclave so that the reaction proceeds under the autogenous pressure of the reaction mixture, and stirring the reaction solution for several hours, for example 12 hours, at elevated temperature, for example 80-160 ° C., preferably 100-150 ° C., in particular 140 ° C.
- the compounds of the formula (1) according to the invention have an unforeseeable, valuable spectrum of pharmacological activity.
- the compounds of formula (I) according to the invention lead to vascular relaxation, platelet aggregation inhibition and to a reduction in blood pressure and to
- the compound of formula (I) according to the invention enhances the action of substances which increase the cGMP level, such as EDRF (endothelium derived relaxing factor), NO donors, protoporphyrin LX, arachidonic acid or
- cardiovascular diseases such as, for example, for the treatment of high blood pressure and cardiac insufficiency, stable and unstable angina pectoris, peripheral and cardiac vascular diseases, of arrhythmias, for the treatment of thromboembolic disorders and ischemia such as myocardial infarction, stroke, transistoric and Ischemic attacks, peripheral circulatory disorders, prevention of restenoses such as after thrombolysis therapies, percutaneous transluminal angioplasties (PTA), percutaneous transluminal coronary angioplasties (PTCA), bypass and for the treatment of cardiovascular diseases such as, for example, for the treatment of high blood pressure and cardiac insufficiency, stable and unstable angina pectoris, peripheral and cardiac vascular diseases, of arrhythmias, for the treatment of thromboembolic disorders and ischemia such as myocardial infarction, stroke, transistoric and Ischemic attacks, peripheral circulatory disorders, prevention of restenoses such as after thrombolysis therapies, percutaneous transluminal angioplasties (PTA), percutaneous transluminal coronary
- Arteriosclerosis asthmatic diseases and diseases of the genitourinary system such as prostate hypertrophy, erectile dysfunction, female sexual dysfunction, osteoporosis, gastroparesis and incontinence are used.
- the compounds of formula (I) described in the present invention are also active compounds for combating diseases in the central nervous system that are characterized by malfunctions of the NO / cGMP system.
- they are suitable for improving perception, concentration performance, learning performance, or memory performance after cognitive disorders, as they occur in particular in situations / diseases / syndromes such as "mild cognitive impairment", age-related learning and memory disorders, age-associated memory loss, vascular dementia, skull Brain trauma, stroke, dementia that occurs after a stroke ("post stroke dementia"), post-traumatic skull brain trauma, general concentration disorders, concentration disorders in children with learning and memory problems, Alzheimer's disease, vascular dementia, dementia with Lewy bodies , Dementia with degeneration of the frontal lobes including Pick's syndrome, Parkinson's disease, progressive nuclear palsy, dementia with corticobasal degeneration, amyolateral sclerosis (ALS), Huntington's disease, multiple sclerosis, thalamic degeneration, Creutzfeld-Jacob dementia, HIV dementia z, schizophrenia with dementia or Kors
- Central nervous system such as anxiety, tension and depression, central nervous system-related sexual dysfunctions and sleep disorders, as well as to regulate pathological disorders in the intake of food, beverages and addictive substances.
- the active ingredients are also suitable for regulating cerebral blood flow and thus represent effective means for combating migraines.
- the compounds of the formula (I) according to the invention can likewise be used to combat painful conditions.
- the compounds according to the invention have anti-inflammatory activity and can therefore be used as anti-inflammatory agents.
- the invention comprises the combination of the compounds of the formula (I) according to the invention with organic nitrates and NO donors.
- Organic nitrates and NO donors in the context of the invention are generally substances which develop their therapeutic effect through the release of NO or NO species. Sodium nitroprusside, nitroglycerin, isosorbide dinitrate, isosorbide mononitrate, molsidomine and SIN-1 are preferred.
- the invention also includes combination with compounds that inhibit the degradation of cyclic guanosine monophosphate (cGMP).
- cGMP cyclic guanosine monophosphate
- These are in particular inhibitors of phosphodiesterases 1, 2 and 5; Nomenclature according to Beavo and Reifsnyder (1990) TiPS 11 pp. 150 to 155. These inhibitors potentiate the activity of the compounds according to the invention and increase the desired pharmacological effect.
- Rabbits are anesthetized and bled by the blow of the neck.
- the aorta is removed, adherent tissue is removed, divided into 1.5 mm wide rings and placed individually in 5 ml organ baths with 37 ° C warm, carbogen-degassed Krebs-Henseleit solution of the following composition (mM): NaCl :
- Glucose 10. The contraction force is recorded with Statham UC2 cells, amplified and digitized via A / D converter (DAS-1802 HC, Keithley Instruments Kunststoff) and recorded in parallel on a line recorder. To create a contraction
- Phenylephrine added cumulatively to the bath in increasing concentration. After several control cycles, the substance to be examined is added to each
- Rats are anesthetized, heparinized and the liver perfused in situ through the portal vein.
- the primary rat hepatocytes are then obtained ex vivo from the liver using collagenase solution.
- the decrease in the substrate to be examined over time was determined bioanalytically (HPLC / UV, HPLC / fluorescence or LC / MSMS) at 5 times in each case in the period from 0-15 min after the start of incubation.
- the clearance was calculated from this using the cell number and liver weight.
- the substance to be examined is administered intravenously as a solution to rats via the tail vein. Blood is drawn from the rats at specified times, this is heparinized and plasma is obtained therefrom by conventional measures. The substance is bioanalytically quantified in plasma. The pharmacokinetic parameters are calculated from the plasma concentration-time curves thus determined using conventional non-compartmental methods used for this.
- the present invention includes pharmaceutical preparations which, in addition to non-toxic, inert pharmaceutically suitable excipients, contain the compound of the formula (I) according to the invention and processes for the preparation of these preparations.
- the active ingredient can optionally also be present in microencapsulated form in one or more of the above-mentioned carriers.
- the therapeutically active compound of formula (I) should be present in the pharmaceutical preparations listed above in a concentration of about 0.1 to 99.5, preferably about 0.5 to 95% by weight of the total mixture.
- the pharmaceutical preparations listed above can also contain further active pharmaceutical ingredients.
- the active compound according to the invention in total amounts of from about 0.01 to about 700, preferably from 0.01 to 100 mg / kg of body weight per 24 hours, if appropriate in the form multiple doses to achieve the desired results.
- a single dose contains the active ingredient according to the invention preferably in amounts of about 0.1 to about 80, in particular 0.1 to 30 mg / kg body weight.
- BABA n-butyl acetate / n-butanol / glacial acetic acid / phosphate buffer pH 6
- Carrier gas helium flow: 1.5 ml / min
- Example HIc are dissolved in 330 ml of THF and mixed with 27 g (341 mmol) of pyridine. Then 47.76 ml (71.66 g, 341 mmol) of trifluoroacetic anhydride are added within 10 min, the temperature rising to 40 ° C. The mixture is stirred overnight at room temperature. The mixture is then poured into 11 water and extracted three times with 0.5 l of ethyl acetate each time. The organic phase is washed with saturated sodium bicarbonate solution and with 1N HCl, dried with MgSO4 and evaporated. Yield: 33.7 g (100% of theory) mp: 81 ° CR f (SiO 2 , TlEl): 0.74
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Psychology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002452590A CA2452590A1 (en) | 2001-07-04 | 2002-06-25 | Morpholine-bridged pyrazolopyridine derivatives |
US10/482,766 US20040235863A1 (en) | 2001-07-04 | 2002-06-25 | Morpholine-bridged pyrazolopyridine derivatives |
JP2003510670A JP2005501034A (ja) | 2001-07-04 | 2002-06-25 | モルホリン架橋のピラゾロピリジン誘導体 |
EP02745409A EP1406908A1 (de) | 2001-07-04 | 2002-06-25 | Morpholin-überbrückte pyrazolopyridinderivate |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10132416.2 | 2001-07-04 | ||
DE10132416A DE10132416A1 (de) | 2001-07-04 | 2001-07-04 | Neue Morpholin-überbrückte Pyrazolopyridinderivate |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003004503A1 true WO2003004503A1 (de) | 2003-01-16 |
Family
ID=7690582
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2002/006991 WO2003004503A1 (de) | 2001-07-04 | 2002-06-25 | Morpholin-überbrückte pyrazolopyridinderivate |
Country Status (6)
Country | Link |
---|---|
US (1) | US20040235863A1 (de) |
EP (1) | EP1406908A1 (de) |
JP (1) | JP2005501034A (de) |
CA (1) | CA2452590A1 (de) |
DE (1) | DE10132416A1 (de) |
WO (1) | WO2003004503A1 (de) |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003095451A1 (de) * | 2002-05-08 | 2003-11-20 | Bayer Healthcare Ag | Carbamat-substituierte pyrazolopyridine |
WO2008031513A1 (de) | 2006-09-15 | 2008-03-20 | Bayer Schering Pharma Aktiengesellschaft | Pyrazolopyridin, indazol, imidazopyridin, imidazopyrimidin, pyrazolopyrazin und pyrazolopyridin derivate als stimulatoren der guanylatcyclase zur herz-kreislauferkrankungen |
DE102007026392A1 (de) | 2007-06-06 | 2008-12-11 | Bayer Healthcare Ag | Lösungen für die Perfusion und Konservierung von Organen und Geweben |
WO2010079120A1 (de) | 2009-01-09 | 2010-07-15 | Bayer Schering Pharma Aktiengesellschaft | Benzimidazol-und pyrazolopyridin-derivate zur behandlung und/oder prävention von herz-kreislauf-erkrankungen |
DE102008063992A1 (de) | 2008-12-19 | 2010-09-02 | Lerner, Zinoviy, Dipl.-Ing. | Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung |
WO2012165399A1 (ja) | 2011-05-30 | 2012-12-06 | アステラス製薬株式会社 | イミダゾピリジン化合物 |
WO2013076168A1 (de) | 2011-11-25 | 2013-05-30 | Bayer Pharma Aktiengesellschaft | Verfahren zur herstellung von substituierten 5-fluor-1h-pyrazolopyridinen |
WO2014084312A1 (ja) | 2012-11-30 | 2014-06-05 | アステラス製薬株式会社 | イミダゾピリジン化合物 |
WO2015063287A1 (en) | 2013-11-01 | 2015-05-07 | Bergen Teknologioverføring As | Activators or stimulators of soluble guanylate cyclase for use in treating chronic fatigue syndrome |
WO2015106268A1 (en) | 2014-01-13 | 2015-07-16 | Ironwood Pharmaceuticals, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS |
WO2016177660A1 (en) | 2015-05-06 | 2016-11-10 | Bayer Pharma Aktiengesellschaft | The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc) |
WO2017013010A1 (de) | 2015-07-23 | 2017-01-26 | Bayer Pharma Aktiengesellschaft | Stimulatoren und/oder aktivatoren der löslichen guanylatzyklase (sgc) in kombination mit einem inhibitor der neutralen endopeptidase (nep inhibitor) und/oder einem angiotensin aii-antagonisten und ihre verwendung |
WO2017106175A2 (en) | 2015-12-14 | 2017-06-22 | Ironwood Pharmaceuticals, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF GASTROINTESTINAL SPHINCTER DYSFUNCTION |
WO2018069126A1 (de) | 2016-10-11 | 2018-04-19 | Bayer Pharma Aktiengesellschaft | Kombination enthaltend sgc stimulatoren und mineralocorticoid-rezeptor-antagonisten |
WO2018111795A2 (en) | 2016-12-13 | 2018-06-21 | Ironwood Pharmaceuticals, Inc. | Use of sgc stimulators for the treatment of esophageal motility disorders |
WO2019219672A1 (en) | 2018-05-15 | 2019-11-21 | Bayer Aktiengesellschaft | 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization |
WO2020014504A1 (en) | 2018-07-11 | 2020-01-16 | Cyclerion Therapeutics, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONRIAL DISORDERS |
WO2020165010A1 (en) | 2019-02-13 | 2020-08-20 | Bayer Aktiengesellschaft | Process for the preparation of porous microparticles |
WO2022057836A1 (zh) * | 2020-09-16 | 2022-03-24 | 南京明德新药研发有限公司 | 苯并脲环衍生物及其制备方法和应用 |
US11331308B2 (en) | 2016-10-11 | 2022-05-17 | Bayer Pharma Aktiengesellschaft | Combination containing sGC activators and mineralocorticoid receptor antagonists |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006005213A1 (de) | 2004-07-08 | 2006-01-19 | Mixpac Systems Ag | Austragvorrichtung für eine einmal-anwendung |
DE102006054757A1 (de) * | 2006-11-21 | 2008-05-29 | Bayer Healthcare Ag | Neue aza-bicyclische Verbindungen und ihre Verwendung |
EP3415515B1 (de) | 2009-11-27 | 2019-12-25 | Adverio Pharma GmbH | Verfahren zur herstellung von methyl-{4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}methylcarbamat |
UY33041A (es) * | 2009-11-27 | 2011-06-30 | Bayer Schering Pharma Aktienegesellschaft | Procedimiento para la preparaciòn de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificaciòn para el uso como principio activo farmacèutico |
DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
EA201390060A1 (ru) | 2010-07-09 | 2013-07-30 | Байер Интеллектуэль Проперти Гмбх | Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний |
EP2590987B1 (de) | 2010-07-09 | 2016-03-09 | Bayer Intellectual Property GmbH | Annellierte 4-aminopyrimidine und ihre verwendung als stimulatoren der löslichen guanylatcyclase |
DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
DE102010043380A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Benzyl-substituierte Carbamate und ihre Verwendung |
DE102010043379A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung |
US9090610B2 (en) | 2011-04-21 | 2015-07-28 | Bayer Intellectual Property Gmbh | Fluoroalkyl-substituted pyrazolopyridines and use thereof |
MX348470B (es) | 2011-09-02 | 2017-06-13 | Bayer Ip Gmbh | Pirimidinas anilladas sustituidas y uso de las mismas. |
DE102012200360A1 (de) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituierte Triazine und ihre Verwendung |
DE102012200352A1 (de) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituierte, annellierte Imidazole und Pyrazole und ihre Verwendung |
DE102012200349A1 (de) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituierte annellierte Pyrimidine und Triazine und ihre Verwendung |
WO2013131923A1 (de) | 2012-03-06 | 2013-09-12 | Bayer Intellectual Property Gmbh | Substituierte azabicyclen und ihre verwendung |
MX2015010725A (es) | 2013-02-21 | 2016-05-31 | Adverio Pharma Gmbh | Formas de metil {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo [3,4-b] piridino-3-il] pirimidino-5-il} metil carbamato. |
BR112015020298A2 (pt) | 2013-03-01 | 2017-07-18 | Bayer Pharma AG | pirimidinas de anel fundido substituídas com trifluormetil e uso das mesmas |
EA201600096A1 (ru) | 2013-07-10 | 2016-10-31 | Байер Фарма Акциенгезельшафт | Бензил-1н-пиразол[3,4-b]пиридины и их применение |
US11242335B2 (en) | 2017-04-11 | 2022-02-08 | Sunshine Lake Pharma Co., Ltd. | Fluorine-substituted indazole compounds and uses thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998023619A1 (de) * | 1996-11-26 | 1998-06-04 | Bayer Aktiengesellschaft | Neue substituierte pyrazolderivate zur behandlung von herzkreislauferkrankungen |
WO2000006568A1 (de) * | 1998-07-29 | 2000-02-10 | Bayer Aktiengesellschaft | Substituierte pyrazolderivate |
WO2000006569A1 (de) * | 1998-07-29 | 2000-02-10 | Bayer Aktiengesellschaft | Mit sechsgliedrigen heterocyclischen ringen kondensierte substituierte pyrazolderivate |
WO2000021954A1 (de) * | 1998-10-09 | 2000-04-20 | Bayer Aktiengesellschaft | Neue heterocyclyl-methyl-substituierte pyrazole |
DE19920352A1 (de) * | 1999-05-04 | 2000-11-09 | Bayer Ag | Substituiertes Pyrazolderivat |
DE10021069A1 (de) * | 2000-04-28 | 2001-10-31 | Bayer Ag | Substituiertes Pyrazolderivat |
-
2001
- 2001-07-04 DE DE10132416A patent/DE10132416A1/de not_active Withdrawn
-
2002
- 2002-06-25 WO PCT/EP2002/006991 patent/WO2003004503A1/de active Application Filing
- 2002-06-25 US US10/482,766 patent/US20040235863A1/en not_active Abandoned
- 2002-06-25 JP JP2003510670A patent/JP2005501034A/ja active Pending
- 2002-06-25 EP EP02745409A patent/EP1406908A1/de not_active Withdrawn
- 2002-06-25 CA CA002452590A patent/CA2452590A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998023619A1 (de) * | 1996-11-26 | 1998-06-04 | Bayer Aktiengesellschaft | Neue substituierte pyrazolderivate zur behandlung von herzkreislauferkrankungen |
WO2000006568A1 (de) * | 1998-07-29 | 2000-02-10 | Bayer Aktiengesellschaft | Substituierte pyrazolderivate |
WO2000006569A1 (de) * | 1998-07-29 | 2000-02-10 | Bayer Aktiengesellschaft | Mit sechsgliedrigen heterocyclischen ringen kondensierte substituierte pyrazolderivate |
WO2000021954A1 (de) * | 1998-10-09 | 2000-04-20 | Bayer Aktiengesellschaft | Neue heterocyclyl-methyl-substituierte pyrazole |
DE19920352A1 (de) * | 1999-05-04 | 2000-11-09 | Bayer Ag | Substituiertes Pyrazolderivat |
DE10021069A1 (de) * | 2000-04-28 | 2001-10-31 | Bayer Ag | Substituiertes Pyrazolderivat |
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HRP20041166B1 (hr) * | 2002-05-08 | 2013-05-31 | Bayer Schering Pharma Aktiengesellschaft | Pirazolopiridini supstituirani s karbamatom |
US7173037B2 (en) | 2002-05-08 | 2007-02-06 | Bayer Healthcare Ag | Carbamate-substituted pyrazolopyridines |
WO2003095451A1 (de) * | 2002-05-08 | 2003-11-20 | Bayer Healthcare Ag | Carbamat-substituierte pyrazolopyridine |
WO2008031513A1 (de) | 2006-09-15 | 2008-03-20 | Bayer Schering Pharma Aktiengesellschaft | Pyrazolopyridin, indazol, imidazopyridin, imidazopyrimidin, pyrazolopyrazin und pyrazolopyridin derivate als stimulatoren der guanylatcyclase zur herz-kreislauferkrankungen |
DE102007026392A1 (de) | 2007-06-06 | 2008-12-11 | Bayer Healthcare Ag | Lösungen für die Perfusion und Konservierung von Organen und Geweben |
DE102008063992A1 (de) | 2008-12-19 | 2010-09-02 | Lerner, Zinoviy, Dipl.-Ing. | Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung |
WO2010079120A1 (de) | 2009-01-09 | 2010-07-15 | Bayer Schering Pharma Aktiengesellschaft | Benzimidazol-und pyrazolopyridin-derivate zur behandlung und/oder prävention von herz-kreislauf-erkrankungen |
DE102009004245A1 (de) | 2009-01-09 | 2010-07-15 | Bayer Schering Pharma Aktiengesellschaft | Neue anellierte, Heteroatom-verbrückte Pyrazol- und Imidazol-Derivate und ihre Verwendung |
WO2012165399A1 (ja) | 2011-05-30 | 2012-12-06 | アステラス製薬株式会社 | イミダゾピリジン化合物 |
EP2896617A1 (de) | 2011-11-25 | 2015-07-22 | Adverio Pharma GmbH | Verfahren zur Herstellung von substituierten 5-Fluor-1H-pyrazolopyridinen |
KR101993022B1 (ko) | 2011-11-25 | 2019-06-25 | 아드베리오 파마 게엠베하 | 치환된 5-플루오로-1h-피라졸로피리딘의 제조 방법 |
KR20140105483A (ko) * | 2011-11-25 | 2014-09-01 | 바이엘 파마 악티엔게젤샤프트 | 치환된 5-플루오로-1h-피라졸로피리딘의 제조 방법 |
WO2013076168A1 (de) | 2011-11-25 | 2013-05-30 | Bayer Pharma Aktiengesellschaft | Verfahren zur herstellung von substituierten 5-fluor-1h-pyrazolopyridinen |
WO2014084312A1 (ja) | 2012-11-30 | 2014-06-05 | アステラス製薬株式会社 | イミダゾピリジン化合物 |
WO2015063287A1 (en) | 2013-11-01 | 2015-05-07 | Bergen Teknologioverføring As | Activators or stimulators of soluble guanylate cyclase for use in treating chronic fatigue syndrome |
WO2015106268A1 (en) | 2014-01-13 | 2015-07-16 | Ironwood Pharmaceuticals, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS |
WO2016177660A1 (en) | 2015-05-06 | 2016-11-10 | Bayer Pharma Aktiengesellschaft | The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc) |
WO2017013010A1 (de) | 2015-07-23 | 2017-01-26 | Bayer Pharma Aktiengesellschaft | Stimulatoren und/oder aktivatoren der löslichen guanylatzyklase (sgc) in kombination mit einem inhibitor der neutralen endopeptidase (nep inhibitor) und/oder einem angiotensin aii-antagonisten und ihre verwendung |
US11166932B2 (en) | 2015-07-23 | 2021-11-09 | Bayer Pharma Aktiengesellschaft | Stimulators and/or activators of soluble guanylate cyclase (sGC) in combination with an inhibitor of neutral endopeptidase (NEP inhibitor) and/or an angiotensin AII antagonist and the use thereof |
WO2017106175A2 (en) | 2015-12-14 | 2017-06-22 | Ironwood Pharmaceuticals, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF GASTROINTESTINAL SPHINCTER DYSFUNCTION |
WO2018069126A1 (de) | 2016-10-11 | 2018-04-19 | Bayer Pharma Aktiengesellschaft | Kombination enthaltend sgc stimulatoren und mineralocorticoid-rezeptor-antagonisten |
US10918639B2 (en) | 2016-10-11 | 2021-02-16 | Bayer Pharma Aktiengesellschaft | Combination containing SGC stimulators and mineralocorticoid receptor antagonists |
US11331308B2 (en) | 2016-10-11 | 2022-05-17 | Bayer Pharma Aktiengesellschaft | Combination containing sGC activators and mineralocorticoid receptor antagonists |
US11684621B2 (en) | 2016-10-11 | 2023-06-27 | Bayer Pharma Aktiengesellschaft | Combination containing sGC stimulators and mineralocorticoid receptor antagonists |
WO2018111795A2 (en) | 2016-12-13 | 2018-06-21 | Ironwood Pharmaceuticals, Inc. | Use of sgc stimulators for the treatment of esophageal motility disorders |
WO2019219672A1 (en) | 2018-05-15 | 2019-11-21 | Bayer Aktiengesellschaft | 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization |
WO2020014504A1 (en) | 2018-07-11 | 2020-01-16 | Cyclerion Therapeutics, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONRIAL DISORDERS |
WO2020165010A1 (en) | 2019-02-13 | 2020-08-20 | Bayer Aktiengesellschaft | Process for the preparation of porous microparticles |
WO2022057836A1 (zh) * | 2020-09-16 | 2022-03-24 | 南京明德新药研发有限公司 | 苯并脲环衍生物及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
US20040235863A1 (en) | 2004-11-25 |
JP2005501034A (ja) | 2005-01-13 |
CA2452590A1 (en) | 2003-01-16 |
DE10132416A1 (de) | 2003-01-16 |
EP1406908A1 (de) | 2004-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003004503A1 (de) | Morpholin-überbrückte pyrazolopyridinderivate | |
EP1339717B1 (de) | Neue carbamat-substituierte pyrazolopyridinderivate | |
EP1339716B1 (de) | lactam-substituierte pyrazolopyridinderivate | |
EP1343786B1 (de) | Neue pyridin-substituierte pyrazolopyridinderivate | |
EP1390365B1 (de) | Neue sulfonat-substituierte pyrazolopyridinderivate | |
EP1339714B1 (de) | Neue sulfonamid-substituierte pyrazolopyridinderivate | |
EP0944631B1 (de) | Neue substituierte pyrazolderivate zur behandlung von herzkreislauferkrankungen | |
EP1506193B1 (de) | Carbamat-substituierte pyrazolopyridine | |
EP1525202B1 (de) | Neue 2,5-disubstituierte pyrimidinderivate | |
DE10232571A1 (de) | 4-Aminosubstituierte Pyrimidinderivate | |
WO2003086407A1 (de) | Verwendung von stimulatoren der löslichen guanylatcyclase zur behandlung von glaukom | |
WO2003097063A1 (de) | Derivate-des 2- (1-benzyl-1h-pyrazolo (3, 4-b) pyridin-3-yl) -5-(4-pyridinyl) -4-pyrimidinamins und ihre verwendung als guanylatcyclase-stimulatoren | |
DE10021069A1 (de) | Substituiertes Pyrazolderivat | |
DE10244810A1 (de) | Neue Morpholin-überbrückte Indazolderivate | |
WO2000066582A1 (de) | Substituiertes pyrazolderivat | |
WO2004031187A1 (de) | Pyridin-substituiertes pyrazolderivat | |
DE10131987A1 (de) | Neue Pyridin-substituierte Pyrazolopyridinderivate | |
DE10122895A1 (de) | Neue Lactam-substituierte Pyrazolopyridinderivate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW GH GM KE LS MW |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002745409 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2452590 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003510670 Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002745409 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10482766 Country of ref document: US |